Table 1

Baseline characteristics of the FAS

SemaglutideLiraglutideTotal
0.05 mg0.1 mg0.2 mg0.3 mgFlexible dose0.3 mg0.6 mg1.2 mg1.8 mgPooled placebo
n646365636464646465129705
Age (years)57.5 (9.8)57.5 (10.0)58.4 (9.6)54.8 (9.7)54.8 (9.7)57.2 (10.8)59.5 (9.8)53.7 (11.4)55.8 (9.2)57.1 (9.2)56.7 (9.9)
HbA1c (%)7.9 (0.7)7.9 (0.8)8.0 (0.8)8.2 (0.8)8.1 (0.9)8.1 (0.9)8.1 (0.8)8.1 (0.9)8.1 (0.8)8.1 (0.9)8.1 (0.8)
FPG (mmol/L, mg/dL)9.3 (2.6), 166.9 (46.9)9.0 (2.2), 161.6 (40.0)9.2 (2.3), 165.7 (41.1)9.7 (2.6), 174.2 (46.2)9.8 (2.7), 177.0 (47.9)9.3 (2.5), 168.0 (45.8)9.3 (2.3), 168.3 (41.9)9.9 (2.7), 178.5 (48.7)9.2 (2.4), 165.5 (44.1)9.7 (3.0), 174.3 (53.8)9.5 (2.6), 170.4 (46.6)
Diabetes duration (years)6.5 (4.6)8.1 (7.3)7.2 (5.7)6.5 (4.4)8.0 (7.1)8.1 (7.1)6.8 (4.6)6.9 (4.9)6.6 (5.2)7.1 (4.5)7.2 (5.6)
Body weight (kg)93.4 (18.3)92.4 (17.2)98.1 (17.9)94.8 (17.8)95.3 (15.4)92.3 (17.5)92.7 (16.5)96.7 (18.3)93.4 (19.3)94.0 (17.8)94.3 (17.6)
BMI (kg/m2)32.3 (4.6)32.4 (4.5)32.8 (4.5)33.1 (4.7)33.2 (4.4)32.9 (3.9)33.0 (4.3)33.3 (4.3)32.1 (4.5)32.8 (4.2)32.8 (4.4)
Female sex31 (48.4)28 (44.4)22 (33.9)31 (49.2)28 (43.8)35 (54.7)32 (50.0)30 (46.9)32 (49.2)57 (44.2)326 (46.2)
Race, n (%)
 Asian6 (9.4)9 (14.3)5 (7.7)7 (11.1)4 (6.3)4 (6.3)2 (3.1)4 (6.3)11 (16.9)14 (10.9)66 (9.4)
 Black or African American9 (14.1)4 (6.3)6 (9.2)11 (17.5)4 (6.3)4 (6.3)4 (6.3)6 (9.4)4 (6.2)11 (8.5)63 (8.9)
 White49 (76.6)50 (79.4)51 (78.5)44 (69.8)52 (81.3)53 (82.8)56 (87.5)54 (84.4)48 (73.8)103 (79.8)560 (79.4)
 Other3 (4.6)1 (1.6)4 (6.3)3 (4.7)2 (3.1)2 (3.1)1 (0.8)16 (2.3)
Ethnicity, n (%)
 Hispanic or Latino9 (14.1)7 (11.1)6 (9.2)4 (6.4)7 (10.9)7 (10.9)6 (9.4)6 (9.4)8 (12.3)16 (12.4)76 (10.8)
 Not Hispanic or Latino55 (85.9)56 (88.9)59 (90.8)59 (93.7)57 (89.1)57 (89.1)58 (90.6)58 (90.6)57 (87.7)113 (87.6)629 (89.2)
Renal function,* n (%)
 Normal (eGFR ≥90 mL/min/1.73 m2)36 (56.3)34 (54.0)34 (52.3)43 (68.3)46 (71.9)39 (60.9)33 (51.6)44 (68.8)45 (69.2)78 (60.5)432 (61.3)
 Mild dysfunction (eGFR 60 to <90 mL/min/1.73 m2)28 (43.8)28 (44.4)31 (47.7)20 (31.7)18 (28.1)24 (37.5)31 (48.4)19 (29.7)20 (30.8)51 (39.5)270 (38.3)
 Moderate dysfunction (eGFR 30 to <60 mL/min/1.73 m2)1 (1.6)1 (1.6)1 (1.6)3 (0.4)
  • Data are means (SD) unless otherwise indicated. eGFR, estimated glomerular filtration rate.

  • *Based on estimated glomerular filtration rate using the MDRD formula.